1. Protein Tyrosine Kinase/RTK
  2. ALK

Ensartinib (Synonyms: X-396)

Cat. No.: HY-16590 Purity: 98.02%
Data Sheet SDS Handling Instructions

Ensartinib is a potent inhibitor of ALK, which is used to treat non-small-cell lung cancer.

For research use only. We do not sell to patients.
Ensartinib Chemical Structure

Ensartinib Chemical Structure

CAS No. : 1365267-27-1

Size Price Stock Quantity
10 mM * 1 mL in DMSO $337 In-stock
2 mg $140 In-stock
5 mg $280 In-stock
10 mg $450 In-stock
25 mg $950 In-stock
50 mg $1500 In-stock
100 mg $2400 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References


Ensartinib is a potent inhibitor of ALK, which is used to treat non-small-cell lung cancer.

In Vitro

Ensartinib is a selective ALK inhibitor, and provids promising advantages in terms of both clinical activity and safety[1].

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT02959619 Betta Pharmaceuticals Co.,Ltd. Solid Tumor|Non-Small Cell Lung Cancer Metastatic November 2016 Phase 1
NCT03213652 National Cancer Institute (NCI) Advanced Malignant Solid Neoplasm|ALK Fusion Protein Expression|ALK Gene Mutation|ALK Gene Translocation|Histiocytosis|Recurrent Childhood Central Nervous System Neoplasm|Recurrent Childhood Non-Hodgkin Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Neuroblastoma|Refractory Central Nervous System Neoplasm|Refractory Malignant Solid Neoplasm|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|ROS1 Fusion Positive|ROS1 Gene Mutation|ROS1 Gene Translocation|Stage III Childhood Non-Hodgk July 24, 2017 Phase 2
NCT02767804 Xcovery Holding Company, LLC Non-small Cell Lung Cancer June 2016 Phase 3
NCT02898116 Ludwig Institute for Cancer Research|MedImmune LLC|Xcovery Holding Company, LLC|Cancer Research Institute, New York City Non-small Cell Lung Cancer|Carcinoma|NSCLC March 1, 2017 Phase 1|Phase 2
NCT01625234 Xcovery Holding Company, LLC Advanced Solid Tumors|Non-small Cell Lung Cancer June 2012 Phase 1|Phase 2
NCT03155620 National Cancer Institute (NCI) Advanced Malignant Solid Neoplasm|Childhood Langerhans Cell Histiocytosis|Histiocytic Sarcoma|Juvenile Xanthogranuloma|Malignant Glioma|Recurrent Central Nervous System Neoplasm|Recurrent Childhood Ependymoma|Recurrent Childhood Malignant Germ Cell Tumor|Recurrent Childhood Medulloblastoma|Recurrent Childhood Non-Hodgkin Lymphoma|Recurrent Childhood Rhabdomyosarcoma|Recurrent Childhood Soft Tissue Sarcoma|Recurrent Ewing Sarcoma|Recurrent Glioma|Recurrent Hepatoblastoma|Recurrent Langerhans Cell July 24, 2017 Phase 2
NCT03215693 Betta Pharmaceuticals Co.,Ltd. Non-Small Cell Lung Cancer September 1, 2017 Phase 2
View MoreCollapse
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 1.8268 mL 9.1339 mL 18.2678 mL
5 mM 0.3654 mL 1.8268 mL 3.6536 mL
10 mM 0.1827 mL 0.9134 mL 1.8268 mL
Molecular Weight






Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 37 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name



Applicant name *


Email address *

Phone number


Organization name *

Country *


Requested quantity *


Bulk Inquiry

Inquiry Information

Product Name:
Cat. No.: